| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 154 | 2025 | 1896 | 18.680 |
Why?
|
| Medication Adherence | 25 | 2020 | 399 | 5.080 |
Why?
|
| Anti-HIV Agents | 30 | 2025 | 322 | 4.770 |
Why?
|
| Patient Compliance | 24 | 2018 | 471 | 4.210 |
Why?
|
| Patient Acceptance of Health Care | 22 | 2018 | 426 | 3.740 |
Why?
|
| Antiretroviral Therapy, Highly Active | 28 | 2015 | 262 | 3.010 |
Why?
|
| Viral Load | 23 | 2020 | 388 | 2.950 |
Why?
|
| Mass Screening | 19 | 2022 | 785 | 2.780 |
Why?
|
| Health Services Accessibility | 15 | 2019 | 605 | 2.700 |
Why?
|
| Anti-Retroviral Agents | 12 | 2025 | 141 | 2.680 |
Why?
|
| Continuity of Patient Care | 9 | 2018 | 150 | 2.560 |
Why?
|
| AIDS Serodiagnosis | 9 | 2019 | 56 | 2.400 |
Why?
|
| Patient-Centered Care | 8 | 2020 | 221 | 2.350 |
Why?
|
| Physician-Patient Relations | 9 | 2018 | 429 | 2.170 |
Why?
|
| Trust | 7 | 2017 | 76 | 2.040 |
Why?
|
| Adult | 119 | 2025 | 29546 | 1.970 |
Why?
|
| Delivery of Health Care | 13 | 2020 | 617 | 1.960 |
Why?
|
| Middle Aged | 103 | 2025 | 26765 | 1.750 |
Why?
|
| HIV | 9 | 2024 | 181 | 1.750 |
Why?
|
| Health Knowledge, Attitudes, Practice | 15 | 2018 | 856 | 1.720 |
Why?
|
| Texas | 39 | 2025 | 3581 | 1.710 |
Why?
|
| Primary Health Care | 12 | 2019 | 775 | 1.640 |
Why?
|
| Male | 142 | 2025 | 61573 | 1.610 |
Why?
|
| Hospitalization | 9 | 2019 | 1791 | 1.570 |
Why?
|
| CD4 Lymphocyte Count | 22 | 2019 | 231 | 1.560 |
Why?
|
| HIV Seropositivity | 5 | 2012 | 124 | 1.510 |
Why?
|
| Health Promotion | 5 | 2017 | 386 | 1.480 |
Why?
|
| Patient Satisfaction | 4 | 2017 | 475 | 1.450 |
Why?
|
| Female | 129 | 2025 | 66827 | 1.440 |
Why?
|
| Young Adult | 47 | 2020 | 9062 | 1.440 |
Why?
|
| Humans | 185 | 2025 | 125375 | 1.390 |
Why?
|
| Ambulatory Care Facilities | 11 | 2022 | 225 | 1.280 |
Why?
|
| Cross-Sectional Studies | 22 | 2024 | 3410 | 1.260 |
Why?
|
| Sexual Behavior | 5 | 2020 | 238 | 1.200 |
Why?
|
| United States | 55 | 2024 | 10913 | 1.200 |
Why?
|
| Community Health Centers | 4 | 2014 | 39 | 1.200 |
Why?
|
| Physicians | 6 | 2022 | 588 | 1.180 |
Why?
|
| Anemia, Sickle Cell | 4 | 2013 | 331 | 1.180 |
Why?
|
| Risk-Taking | 3 | 2020 | 96 | 1.170 |
Why?
|
| Veterans | 15 | 2023 | 1726 | 1.160 |
Why?
|
| Social Support | 5 | 2020 | 340 | 1.130 |
Why?
|
| Ambulatory Care | 6 | 2015 | 391 | 1.120 |
Why?
|
| Child Health Services | 3 | 2013 | 87 | 1.080 |
Why?
|
| Healthcare Disparities | 5 | 2024 | 439 | 1.060 |
Why?
|
| Surveys and Questionnaires | 17 | 2025 | 3689 | 1.040 |
Why?
|
| Medicare | 5 | 2024 | 427 | 1.000 |
Why?
|
| Disease Transmission, Infectious | 2 | 2018 | 84 | 0.990 |
Why?
|
| Peer Group | 3 | 2018 | 118 | 0.970 |
Why?
|
| Hepatitis C | 11 | 2010 | 367 | 0.960 |
Why?
|
| Cohort Studies | 36 | 2023 | 4829 | 0.930 |
Why?
|
| Adolescent | 46 | 2020 | 19432 | 0.930 |
Why?
|
| Serologic Tests | 3 | 2020 | 118 | 0.920 |
Why?
|
| Communication | 5 | 2022 | 510 | 0.910 |
Why?
|
| Homosexuality, Male | 7 | 2020 | 63 | 0.910 |
Why?
|
| Drug Prescriptions | 2 | 2024 | 221 | 0.890 |
Why?
|
| Physicians, Primary Care | 2 | 2016 | 94 | 0.880 |
Why?
|
| Quality of Health Care | 3 | 2013 | 391 | 0.830 |
Why?
|
| Telemedicine | 4 | 2024 | 437 | 0.830 |
Why?
|
| HIV-1 | 7 | 2022 | 464 | 0.800 |
Why?
|
| Sexual and Gender Minorities | 2 | 2020 | 64 | 0.780 |
Why?
|
| Pre-Exposure Prophylaxis | 3 | 2019 | 36 | 0.750 |
Why?
|
| Appointments and Schedules | 5 | 2015 | 49 | 0.750 |
Why?
|
| Prospective Studies | 17 | 2023 | 6141 | 0.710 |
Why?
|
| Health Care Surveys | 7 | 2016 | 283 | 0.710 |
Why?
|
| Aged | 40 | 2024 | 19722 | 0.700 |
Why?
|
| Text Messaging | 2 | 2019 | 33 | 0.700 |
Why?
|
| Health Services Needs and Demand | 4 | 2019 | 171 | 0.690 |
Why?
|
| Survivors | 2 | 2015 | 339 | 0.690 |
Why?
|
| Practice Guidelines as Topic | 4 | 2018 | 1270 | 0.690 |
Why?
|
| Substance-Related Disorders | 4 | 2021 | 460 | 0.690 |
Why?
|
| Chronic Disease | 3 | 2015 | 1189 | 0.670 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2020 | 40 | 0.670 |
Why?
|
| Insurance, Health | 2 | 2018 | 140 | 0.630 |
Why?
|
| Patient Participation | 2 | 2019 | 219 | 0.630 |
Why?
|
| Soft Tissue Infections | 1 | 2020 | 85 | 0.630 |
Why?
|
| Early Medical Intervention | 2 | 2016 | 30 | 0.610 |
Why?
|
| Community-Acquired Infections | 2 | 2020 | 241 | 0.600 |
Why?
|
| Health Services | 2 | 2015 | 70 | 0.590 |
Why?
|
| Dementia | 1 | 2023 | 451 | 0.580 |
Why?
|
| Attitude to Health | 5 | 2018 | 256 | 0.580 |
Why?
|
| Internal Medicine | 2 | 2023 | 150 | 0.580 |
Why?
|
| Unsafe Sex | 1 | 2017 | 22 | 0.570 |
Why?
|
| Community Health Workers | 4 | 2015 | 65 | 0.570 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2020 | 220 | 0.570 |
Why?
|
| Cognition | 1 | 2022 | 723 | 0.560 |
Why?
|
| Office Visits | 2 | 2019 | 76 | 0.560 |
Why?
|
| Interviews as Topic | 6 | 2019 | 373 | 0.560 |
Why?
|
| Infectious Disease Transmission, Vertical | 4 | 2015 | 243 | 0.560 |
Why?
|
| Patient Selection | 3 | 2017 | 696 | 0.550 |
Why?
|
| Drug Monitoring | 2 | 2025 | 171 | 0.550 |
Why?
|
| Behavior Therapy | 5 | 2016 | 256 | 0.550 |
Why?
|
| Mentors | 3 | 2016 | 149 | 0.550 |
Why?
|
| Patient Outcome Assessment | 2 | 2022 | 92 | 0.540 |
Why?
|
| Hospitals, Pediatric | 2 | 2013 | 768 | 0.540 |
Why?
|
| Counseling | 1 | 2018 | 220 | 0.530 |
Why?
|
| Retrospective Studies | 40 | 2023 | 16370 | 0.520 |
Why?
|
| Program Evaluation | 6 | 2019 | 440 | 0.500 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 798 | 0.500 |
Why?
|
| Health Personnel | 3 | 2025 | 509 | 0.490 |
Why?
|
| Socioeconomic Factors | 7 | 2015 | 859 | 0.490 |
Why?
|
| Hospitals, Veterans | 3 | 2017 | 357 | 0.490 |
Why?
|
| Guideline Adherence | 2 | 2018 | 375 | 0.490 |
Why?
|
| Sickness Impact Profile | 1 | 2015 | 35 | 0.490 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2018 | 733 | 0.480 |
Why?
|
| Reverse Transcriptase Inhibitors | 3 | 2011 | 36 | 0.470 |
Why?
|
| Community Health Services | 3 | 2018 | 88 | 0.470 |
Why?
|
| Urban Population | 6 | 2023 | 229 | 0.460 |
Why?
|
| Health Education | 3 | 2015 | 221 | 0.460 |
Why?
|
| Communication Barriers | 1 | 2014 | 37 | 0.450 |
Why?
|
| Anxiety | 3 | 2021 | 944 | 0.450 |
Why?
|
| Emergency Service, Hospital | 6 | 2018 | 1074 | 0.450 |
Why?
|
| Psychometrics | 2 | 2015 | 647 | 0.450 |
Why?
|
| Veterans Health | 1 | 2016 | 176 | 0.450 |
Why?
|
| Marketing of Health Services | 1 | 2014 | 25 | 0.440 |
Why?
|
| Reminder Systems | 2 | 2011 | 60 | 0.430 |
Why?
|
| Qualitative Research | 7 | 2019 | 538 | 0.430 |
Why?
|
| Role | 1 | 2013 | 26 | 0.430 |
Why?
|
| Protease Inhibitors | 2 | 2015 | 96 | 0.420 |
Why?
|
| Inpatients | 3 | 2023 | 501 | 0.420 |
Why?
|
| Social Marketing | 1 | 2013 | 9 | 0.410 |
Why?
|
| Depression | 6 | 2022 | 1232 | 0.410 |
Why?
|
| Risk Factors | 18 | 2022 | 10298 | 0.400 |
Why?
|
| Patient Preference | 1 | 2014 | 118 | 0.400 |
Why?
|
| Public Health | 2 | 2016 | 267 | 0.390 |
Why?
|
| Internship and Residency | 2 | 2023 | 1183 | 0.390 |
Why?
|
| Hospitals, Urban | 2 | 2015 | 97 | 0.390 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2019 | 160 | 0.380 |
Why?
|
| Quality of Life | 4 | 2015 | 1909 | 0.380 |
Why?
|
| Multivariate Analysis | 9 | 2015 | 1427 | 0.380 |
Why?
|
| Syphilis, Cutaneous | 1 | 2011 | 4 | 0.370 |
Why?
|
| Skin Ulcer | 1 | 2011 | 32 | 0.370 |
Why?
|
| Hospitals, General | 1 | 2011 | 23 | 0.360 |
Why?
|
| Delayed Diagnosis | 1 | 2013 | 126 | 0.360 |
Why?
|
| Language | 1 | 2013 | 196 | 0.360 |
Why?
|
| Anus Neoplasms | 4 | 2015 | 38 | 0.360 |
Why?
|
| Sexually Transmitted Diseases, Viral | 1 | 2010 | 4 | 0.360 |
Why?
|
| Disabled Children | 1 | 2011 | 24 | 0.360 |
Why?
|
| Poverty | 3 | 2015 | 421 | 0.360 |
Why?
|
| Parent-Child Relations | 1 | 2013 | 247 | 0.350 |
Why?
|
| Smoking Cessation | 2 | 2024 | 198 | 0.350 |
Why?
|
| Attitude of Health Personnel | 4 | 2025 | 674 | 0.350 |
Why?
|
| Lost to Follow-Up | 3 | 2022 | 33 | 0.350 |
Why?
|
| Interpersonal Relations | 1 | 2012 | 222 | 0.350 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2010 | 9 | 0.350 |
Why?
|
| Syphilis | 1 | 2011 | 97 | 0.350 |
Why?
|
| Motivation | 1 | 2013 | 319 | 0.340 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2011 | 140 | 0.340 |
Why?
|
| Communications Media | 1 | 2010 | 4 | 0.340 |
Why?
|
| Pain Measurement | 4 | 2014 | 344 | 0.330 |
Why?
|
| Time Factors | 9 | 2018 | 6313 | 0.330 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2009 | 933 | 0.320 |
Why?
|
| Vascular Diseases | 1 | 2011 | 155 | 0.320 |
Why?
|
| Reproducibility of Results | 5 | 2021 | 2881 | 0.320 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2024 | 1119 | 0.320 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2015 | 456 | 0.320 |
Why?
|
| Itraconazole | 1 | 2009 | 25 | 0.320 |
Why?
|
| Treatment Outcome | 14 | 2016 | 12287 | 0.310 |
Why?
|
| Self Administration | 2 | 2011 | 43 | 0.310 |
Why?
|
| Sierra Leone | 4 | 2018 | 30 | 0.310 |
Why?
|
| Electronic Health Records | 4 | 2024 | 726 | 0.310 |
Why?
|
| Pilot Projects | 5 | 2024 | 1399 | 0.310 |
Why?
|
| Histoplasmosis | 1 | 2009 | 48 | 0.310 |
Why?
|
| Emergency Medical Services | 1 | 2013 | 398 | 0.300 |
Why?
|
| Regression Analysis | 4 | 2015 | 778 | 0.290 |
Why?
|
| Liver Neoplasms | 3 | 2009 | 1316 | 0.290 |
Why?
|
| Alcoholism | 2 | 2023 | 230 | 0.290 |
Why?
|
| Sleep Wake Disorders | 3 | 2014 | 168 | 0.280 |
Why?
|
| Thyroid Neoplasms | 2 | 2007 | 189 | 0.280 |
Why?
|
| Cholangiocarcinoma | 1 | 2009 | 107 | 0.280 |
Why?
|
| Bile Duct Neoplasms | 1 | 2009 | 109 | 0.280 |
Why?
|
| Self Efficacy | 3 | 2013 | 199 | 0.270 |
Why?
|
| Health Plan Implementation | 2 | 2018 | 41 | 0.260 |
Why?
|
| Patient Education as Topic | 4 | 2019 | 443 | 0.260 |
Why?
|
| Databases, Factual | 1 | 2011 | 1174 | 0.260 |
Why?
|
| Prevalence | 8 | 2015 | 2467 | 0.260 |
Why?
|
| Public Health Practice | 2 | 2016 | 20 | 0.250 |
Why?
|
| Self Report | 3 | 2021 | 509 | 0.250 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2007 | 223 | 0.250 |
Why?
|
| Prisoners | 4 | 2010 | 35 | 0.240 |
Why?
|
| Pancreatic Neoplasms | 2 | 2009 | 690 | 0.240 |
Why?
|
| Logistic Models | 4 | 2015 | 1802 | 0.240 |
Why?
|
| Internet | 1 | 2007 | 375 | 0.230 |
Why?
|
| Neuropsychological Tests | 3 | 2023 | 907 | 0.230 |
Why?
|
| Infant | 9 | 2015 | 12606 | 0.230 |
Why?
|
| Pediatrics | 1 | 2013 | 1159 | 0.220 |
Why?
|
| Patient Care | 2 | 2016 | 100 | 0.220 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2015 | 669 | 0.220 |
Why?
|
| Eosinophilia | 2 | 2014 | 101 | 0.210 |
Why?
|
| Teaching Rounds | 1 | 2023 | 28 | 0.210 |
Why?
|
| Cell Phone | 2 | 2014 | 30 | 0.210 |
Why?
|
| Child, Preschool | 7 | 2015 | 14154 | 0.200 |
Why?
|
| Mobile Applications | 1 | 2024 | 88 | 0.200 |
Why?
|
| Parents | 3 | 2015 | 1024 | 0.200 |
Why?
|
| Creativity | 1 | 2022 | 13 | 0.200 |
Why?
|
| Health Policy | 2 | 2014 | 214 | 0.190 |
Why?
|
| Liver Cirrhosis | 3 | 2007 | 859 | 0.190 |
Why?
|
| Survival Analysis | 5 | 2009 | 1495 | 0.190 |
Why?
|
| HIV Antibodies | 2 | 2022 | 69 | 0.190 |
Why?
|
| Executive Function | 1 | 2022 | 110 | 0.190 |
Why?
|
| Child | 9 | 2016 | 24626 | 0.190 |
Why?
|
| Culture | 2 | 2012 | 68 | 0.180 |
Why?
|
| Rural Population | 1 | 2023 | 257 | 0.180 |
Why?
|
| Longitudinal Studies | 4 | 2019 | 1320 | 0.180 |
Why?
|
| Pain | 2 | 2014 | 448 | 0.180 |
Why?
|
| Staphylococcus aureus | 2 | 2020 | 463 | 0.180 |
Why?
|
| Disabled Persons | 1 | 2022 | 92 | 0.180 |
Why?
|
| Trypanosoma cruzi | 1 | 2024 | 236 | 0.180 |
Why?
|
| Mentoring | 1 | 2022 | 76 | 0.170 |
Why?
|
| Housing | 1 | 2020 | 53 | 0.170 |
Why?
|
| Emigrants and Immigrants | 2 | 2013 | 142 | 0.170 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 1104 | 0.170 |
Why?
|
| Early Diagnosis | 2 | 2014 | 184 | 0.170 |
Why?
|
| Chagas Disease | 1 | 2024 | 295 | 0.170 |
Why?
|
| Prisons | 2 | 2010 | 11 | 0.170 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2003 | 383 | 0.160 |
Why?
|
| Social Stigma | 1 | 2020 | 72 | 0.160 |
Why?
|
| Risk Assessment | 5 | 2015 | 3431 | 0.160 |
Why?
|
| Incidence | 9 | 2015 | 3134 | 0.160 |
Why?
|
| Memory Disorders | 1 | 2021 | 229 | 0.160 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 6558 | 0.160 |
Why?
|
| Hyperaldosteronism | 1 | 2019 | 16 | 0.160 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2019 | 9 | 0.160 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2012 | 815 | 0.150 |
Why?
|
| House Calls | 1 | 2018 | 37 | 0.150 |
Why?
|
| Drug Therapy, Combination | 3 | 2011 | 1172 | 0.150 |
Why?
|
| Chicago | 1 | 2018 | 20 | 0.150 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 5172 | 0.150 |
Why?
|
| Patients | 1 | 2019 | 120 | 0.150 |
Why?
|
| Linear Models | 2 | 2013 | 683 | 0.150 |
Why?
|
| Case-Control Studies | 5 | 2018 | 3313 | 0.150 |
Why?
|
| HIV Core Protein p24 | 1 | 2018 | 12 | 0.150 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 344 | 0.150 |
Why?
|
| HIV Serosorting | 1 | 2017 | 1 | 0.140 |
Why?
|
| Intention | 3 | 2013 | 92 | 0.140 |
Why?
|
| Mental Health | 1 | 2021 | 340 | 0.140 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 2057 | 0.140 |
Why?
|
| Health Communication | 1 | 2018 | 27 | 0.140 |
Why?
|
| Condoms | 1 | 2017 | 49 | 0.140 |
Why?
|
| Minority Health | 1 | 2017 | 11 | 0.140 |
Why?
|
| Tuberculosis | 1 | 2003 | 527 | 0.140 |
Why?
|
| Waiting Lists | 1 | 2019 | 227 | 0.140 |
Why?
|
| Factor Analysis, Statistical | 2 | 2015 | 218 | 0.140 |
Why?
|
| Minority Groups | 2 | 2013 | 243 | 0.140 |
Why?
|
| Sexual Partners | 1 | 2017 | 87 | 0.140 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 195 | 0.130 |
Why?
|
| Medically Underserved Area | 1 | 2017 | 89 | 0.130 |
Why?
|
| Perception | 1 | 2018 | 220 | 0.130 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2019 | 209 | 0.130 |
Why?
|
| Risk | 2 | 2009 | 759 | 0.120 |
Why?
|
| Antiviral Agents | 3 | 2010 | 768 | 0.120 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 136 | 0.120 |
Why?
|
| Sex Factors | 3 | 2010 | 1275 | 0.120 |
Why?
|
| Self-Assessment | 1 | 2015 | 65 | 0.120 |
Why?
|
| Liver Diseases | 3 | 2007 | 368 | 0.120 |
Why?
|
| Survival Rate | 3 | 2010 | 2051 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 1654 | 0.120 |
Why?
|
| Cities | 1 | 2014 | 47 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2005 | 136 | 0.110 |
Why?
|
| Splints | 1 | 2013 | 9 | 0.110 |
Why?
|
| Hepacivirus | 3 | 2010 | 248 | 0.110 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2014 | 76 | 0.110 |
Why?
|
| Hepatitis C, Chronic | 2 | 2010 | 344 | 0.110 |
Why?
|
| Visual Analog Scale | 1 | 2013 | 7 | 0.110 |
Why?
|
| Professional-Patient Relations | 1 | 2014 | 84 | 0.110 |
Why?
|
| Neuralgia | 1 | 2013 | 45 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 887 | 0.110 |
Why?
|
| Patient Advocacy | 1 | 2013 | 62 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 2430 | 0.100 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2014 | 121 | 0.100 |
Why?
|
| Failure to Thrive | 1 | 2013 | 90 | 0.100 |
Why?
|
| Violence | 1 | 2013 | 114 | 0.100 |
Why?
|
| Centralized Hospital Services | 1 | 2012 | 5 | 0.100 |
Why?
|
| Emtricitabine | 1 | 2012 | 2 | 0.100 |
Why?
|
| Homosexuality | 2 | 2010 | 18 | 0.100 |
Why?
|
| Tenofovir | 1 | 2012 | 18 | 0.100 |
Why?
|
| Organophosphonates | 1 | 2012 | 20 | 0.100 |
Why?
|
| Adaptation, Psychological | 1 | 2015 | 431 | 0.100 |
Why?
|
| Benzoxazines | 1 | 2012 | 23 | 0.100 |
Why?
|
| Alkynes | 1 | 2012 | 25 | 0.100 |
Why?
|
| Pneumonia, Pneumococcal | 2 | 2009 | 83 | 0.100 |
Why?
|
| Cyclopropanes | 1 | 2012 | 67 | 0.090 |
Why?
|
| Deoxycytidine | 1 | 2012 | 78 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2015 | 372 | 0.090 |
Why?
|
| Spouses | 1 | 2012 | 65 | 0.090 |
Why?
|
| Health Surveys | 1 | 2013 | 243 | 0.090 |
Why?
|
| Disease Progression | 3 | 2019 | 2084 | 0.090 |
Why?
|
| Adenine | 1 | 2012 | 104 | 0.090 |
Why?
|
| Motivational Interviewing | 1 | 2012 | 46 | 0.090 |
Why?
|
| Stereotyping | 1 | 2011 | 18 | 0.090 |
Why?
|
| Child, Exceptional | 1 | 2011 | 3 | 0.090 |
Why?
|
| ROC Curve | 1 | 2013 | 572 | 0.090 |
Why?
|
| Video Recording | 1 | 2013 | 186 | 0.090 |
Why?
|
| Community-Institutional Relations | 1 | 2011 | 30 | 0.090 |
Why?
|
| Poisson Distribution | 1 | 2011 | 51 | 0.090 |
Why?
|
| Family Practice | 1 | 2011 | 91 | 0.090 |
Why?
|
| Rural Health | 1 | 2011 | 50 | 0.090 |
Why?
|
| Niacin | 1 | 2011 | 58 | 0.090 |
Why?
|
| Fenofibrate | 1 | 2011 | 59 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 511 | 0.090 |
Why?
|
| Sulfamethizole | 1 | 2010 | 1 | 0.090 |
Why?
|
| Trimethoprim | 1 | 2010 | 4 | 0.090 |
Why?
|
| Dapsone | 1 | 2010 | 6 | 0.090 |
Why?
|
| Genes, pol | 1 | 2010 | 10 | 0.090 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2010 | 16 | 0.090 |
Why?
|
| Adiponectin | 1 | 2011 | 113 | 0.090 |
Why?
|
| Costs and Cost Analysis | 1 | 2011 | 163 | 0.090 |
Why?
|
| Anemia, Hemolytic | 1 | 2010 | 30 | 0.090 |
Why?
|
| Safe Sex | 1 | 2010 | 16 | 0.090 |
Why?
|
| Focus Groups | 1 | 2011 | 191 | 0.090 |
Why?
|
| Drug Resistance, Viral | 1 | 2010 | 47 | 0.090 |
Why?
|
| Affect | 1 | 2011 | 156 | 0.090 |
Why?
|
| Life Expectancy | 1 | 2010 | 53 | 0.080 |
Why?
|
| Disability Evaluation | 1 | 2011 | 179 | 0.080 |
Why?
|
| Health Facilities | 1 | 2010 | 61 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2013 | 471 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 145 | 0.080 |
Why?
|
| Viremia | 1 | 2010 | 129 | 0.080 |
Why?
|
| Needs Assessment | 1 | 2011 | 174 | 0.080 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 85 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2010 | 265 | 0.080 |
Why?
|
| Disease Management | 1 | 2013 | 530 | 0.080 |
Why?
|
| Hepatitis B | 2 | 2008 | 161 | 0.080 |
Why?
|
| Age Factors | 3 | 2011 | 2818 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 1315 | 0.080 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2009 | 13 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 159 | 0.080 |
Why?
|
| Pregnancy | 5 | 2015 | 7226 | 0.080 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2009 | 28 | 0.080 |
Why?
|
| Haemophilus Infections | 1 | 2009 | 91 | 0.080 |
Why?
|
| Haemophilus influenzae | 1 | 2009 | 130 | 0.080 |
Why?
|
| Health Resources | 2 | 2014 | 116 | 0.080 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2009 | 49 | 0.080 |
Why?
|
| Physician's Role | 1 | 2010 | 168 | 0.080 |
Why?
|
| Research | 1 | 2010 | 263 | 0.080 |
Why?
|
| Informed Consent | 1 | 2011 | 333 | 0.070 |
Why?
|
| Neoplasms | 2 | 2015 | 2799 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2009 | 255 | 0.070 |
Why?
|
| Pneumonia, Bacterial | 1 | 2009 | 77 | 0.070 |
Why?
|
| Cause of Death | 2 | 2014 | 474 | 0.070 |
Why?
|
| Pediatric Obesity | 1 | 2013 | 383 | 0.070 |
Why?
|
| Dyslipidemias | 1 | 2011 | 235 | 0.070 |
Why?
|
| Malawi | 3 | 2015 | 398 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2022 | 762 | 0.070 |
Why?
|
| Hyperglycemia | 1 | 2009 | 227 | 0.070 |
Why?
|
| SEER Program | 1 | 2009 | 202 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2010 | 264 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2011 | 2909 | 0.070 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2007 | 44 | 0.070 |
Why?
|
| Odds Ratio | 4 | 2013 | 1253 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 515 | 0.070 |
Why?
|
| Cryoglobulinemia | 1 | 2007 | 10 | 0.070 |
Why?
|
| Social Class | 1 | 2008 | 190 | 0.070 |
Why?
|
| Neurocysticercosis | 1 | 2007 | 27 | 0.070 |
Why?
|
| International Classification of Diseases | 1 | 2007 | 92 | 0.070 |
Why?
|
| Infant, Newborn | 3 | 2022 | 8274 | 0.070 |
Why?
|
| Metabolic Syndrome | 1 | 2010 | 342 | 0.070 |
Why?
|
| Streptococcus pneumoniae | 1 | 2009 | 376 | 0.070 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2007 | 166 | 0.070 |
Why?
|
| Prejudice | 1 | 2006 | 37 | 0.060 |
Why?
|
| Acute Coronary Syndrome | 1 | 2009 | 214 | 0.060 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2007 | 668 | 0.060 |
Why?
|
| Papanicolaou Test | 1 | 2006 | 33 | 0.060 |
Why?
|
| Vaginal Smears | 1 | 2006 | 48 | 0.060 |
Why?
|
| Asthma | 1 | 2013 | 756 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 1362 | 0.060 |
Why?
|
| Pandemics | 2 | 2023 | 1113 | 0.060 |
Why?
|
| Urban Health Services | 1 | 2005 | 22 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2013 | 818 | 0.060 |
Why?
|
| Carcinoma, Papillary | 1 | 2006 | 71 | 0.060 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2007 | 120 | 0.060 |
Why?
|
| Medical Records | 1 | 2005 | 191 | 0.060 |
Why?
|
| Calreticulin | 1 | 2004 | 20 | 0.060 |
Why?
|
| San Francisco | 1 | 2004 | 17 | 0.060 |
Why?
|
| Uncompensated Care | 1 | 2004 | 10 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2005 | 338 | 0.060 |
Why?
|
| Smokers | 1 | 2024 | 40 | 0.060 |
Why?
|
| Osteomyelitis | 1 | 2007 | 209 | 0.050 |
Why?
|
| Liver Failure, Acute | 1 | 2005 | 89 | 0.050 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2005 | 173 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2006 | 284 | 0.050 |
Why?
|
| Telephone | 1 | 2023 | 110 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 730 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2003 | 404 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2003 | 78 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2006 | 296 | 0.050 |
Why?
|
| DNA, Bacterial | 1 | 2003 | 475 | 0.050 |
Why?
|
| Comorbidity | 2 | 2021 | 1528 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2004 | 384 | 0.050 |
Why?
|
| RNA, Viral | 3 | 2010 | 538 | 0.050 |
Why?
|
| Staphylococcal Infections | 1 | 2007 | 562 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2005 | 544 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2004 | 433 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2003 | 314 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2006 | 1028 | 0.040 |
Why?
|
| Machine Learning | 1 | 2024 | 251 | 0.040 |
Why?
|
| Feedback | 1 | 2022 | 165 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 394 | 0.040 |
Why?
|
| Data Collection | 2 | 2013 | 381 | 0.040 |
Why?
|
| Lebanon | 1 | 2020 | 5 | 0.040 |
Why?
|
| Proteomics | 1 | 2004 | 506 | 0.040 |
Why?
|
| Mental Recall | 1 | 2021 | 142 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2020 | 43 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2008 | 828 | 0.040 |
Why?
|
| Patient Navigation | 1 | 2020 | 25 | 0.040 |
Why?
|
| Pharmacists | 1 | 2020 | 86 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 29 | 0.040 |
Why?
|
| Smoking | 1 | 2005 | 1048 | 0.040 |
Why?
|
| Software | 1 | 2024 | 687 | 0.040 |
Why?
|
| Registries | 2 | 2019 | 1434 | 0.040 |
Why?
|
| Directly Observed Therapy | 1 | 2018 | 25 | 0.040 |
Why?
|
| Prognosis | 4 | 2012 | 4686 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2009 | 283 | 0.040 |
Why?
|
| Tablets | 1 | 2018 | 27 | 0.040 |
Why?
|
| Health Services Research | 1 | 2019 | 186 | 0.040 |
Why?
|
| Algorithms | 1 | 2024 | 1633 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 118 | 0.030 |
Why?
|
| Uganda | 1 | 2017 | 79 | 0.030 |
Why?
|
| Adrenal Glands | 1 | 1996 | 43 | 0.030 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1996 | 67 | 0.030 |
Why?
|
| Probability | 2 | 2007 | 318 | 0.030 |
Why?
|
| Adenoma | 1 | 1996 | 128 | 0.030 |
Why?
|
| District of Columbia | 1 | 2014 | 17 | 0.030 |
Why?
|
| Financial Support | 1 | 2014 | 8 | 0.030 |
Why?
|
| Health Behavior | 1 | 2018 | 383 | 0.030 |
Why?
|
| Program Development | 1 | 2016 | 183 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 2182 | 0.030 |
Why?
|
| Walk Test | 1 | 2014 | 24 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2007 | 2096 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2014 | 93 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2015 | 161 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 658 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 1996 | 357 | 0.030 |
Why?
|
| Exanthema | 1 | 2014 | 71 | 0.030 |
Why?
|
| Premedication | 1 | 2013 | 41 | 0.030 |
Why?
|
| Standard of Care | 1 | 2014 | 130 | 0.030 |
Why?
|
| Exercise Test | 1 | 2014 | 254 | 0.030 |
Why?
|
| Mortality | 1 | 2014 | 238 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2012 | 74 | 0.020 |
Why?
|
| Community Networks | 1 | 2012 | 33 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2013 | 178 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 309 | 0.020 |
Why?
|
| Sleep | 1 | 2013 | 346 | 0.020 |
Why?
|
| Mutation | 2 | 2019 | 5905 | 0.020 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2010 | 92 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2011 | 183 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2012 | 348 | 0.020 |
Why?
|
| Health Planning | 1 | 2009 | 16 | 0.020 |
Why?
|
| Alabama | 1 | 2009 | 45 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2009 | 52 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2010 | 220 | 0.020 |
Why?
|
| Triglycerides | 1 | 2011 | 576 | 0.020 |
Why?
|
| Life Style | 1 | 2011 | 415 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2009 | 203 | 0.020 |
Why?
|
| Anticholesteremic Agents | 1 | 2010 | 235 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 1634 | 0.020 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2007 | 57 | 0.020 |
Why?
|
| Methicillin Resistance | 1 | 2007 | 118 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2006 | 23 | 0.020 |
Why?
|
| Rifampin | 1 | 2007 | 131 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 1065 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 2006 | 71 | 0.020 |
Why?
|
| Papillomaviridae | 1 | 2006 | 145 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2007 | 554 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2009 | 494 | 0.020 |
Why?
|
| Exercise | 1 | 2011 | 814 | 0.010 |
Why?
|
| Research Design | 1 | 2009 | 693 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 2005 | 100 | 0.010 |
Why?
|
| Vancomycin | 1 | 2007 | 217 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2006 | 418 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2007 | 683 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2004 | 42 | 0.010 |
Why?
|
| Genotype | 1 | 2010 | 2570 | 0.010 |
Why?
|
| Glycosylation | 1 | 2004 | 124 | 0.010 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2006 | 193 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 1240 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 418 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 1704 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 719 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2004 | 296 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2004 | 404 | 0.010 |
Why?
|
| Drug Therapy | 1 | 2003 | 87 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2004 | 335 | 0.010 |
Why?
|
| Pancreatitis | 1 | 2004 | 133 | 0.010 |
Why?
|
| Liver | 1 | 2010 | 1749 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 1111 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2004 | 248 | 0.010 |
Why?
|
| Biomarkers | 1 | 2010 | 3106 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 1033 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 2718 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2004 | 910 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 3900 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 1756 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2004 | 1025 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1996 | 295 | 0.010 |
Why?
|